Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 15/20 | 0.73 |
| ▸ | NPC1 | O15118 | 13/20 | 0.73 |
| ▸ | CASP3 | P42574 | 1/20 | 0.73 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.73 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.73 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.67 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.66 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.66 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25215660 | 0.87 | GPR142 (0.71) | KMT2AMEN1GAARAB9ANPC1 | |
| SCHEMBL30378238 | 0.87 | GPR142 (0.64) | KMT2AMEN1GAARAB9ANPC1 | |
| SCHEMBL25574626 | 0.87 | GPR142 (0.64) | KMT2AMEN1GAARAB9ANPC1 | |
| SCHEMBL25203241 | 0.87 | GPR142 (0.64) | KMT2AMEN1GAARAB9ANPC1 | |
| SCHEMBL25211440 | 0.87 | GPR142 (0.71) | KMT2AMEN1GAARAB9ANPC1 | |
| SCHEMBL25212955 | 0.86 | NPC1 (0.58) | KMT2AMEN1GAARAB9ANPC1 | |
| SCHEMBL25243755 | 0.86 | TRPV1 (0.60) | KMT2AMEN1GAARAB9ANPC1 | |
| SCHEMBL25208411 | 0.86 | KMT2A (0.65) | KMT2AMEN1GAARAB9ANPC1 | |
| SCHEMBL25574412 | 0.86 | KMT2A (0.65) | KMT2AMEN1GAARAB9ANPC1 | |
| SCHEMBL25234074 | 0.85 | GPR142 (0.68) | KMT2AMEN1GAARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174530-A1 | N-(PHENYLAMINOCARBONYL) TETRAHYDRO-ISOQUINOLINES AND RELATED COMPOUNDS AS MODULATORS OF GPR65 | Pathios Therapeutics Limited (GB) | 2023-06-08 | — | — | US | claimed |
| EP-4161643-A1 | N-(PHENYLAMINOCARBONYL) TETRAHYDRO-ISOQUINOLINES AND RELATED COMPOUNDS AS MODULATORS OF GPR65 | Pathios Therapeutics Limited (GB) | 2023-04-12 | — | — | EP | claimed |
| US-20230174530-A1 | N-(PHENYLAMINOCARBONYL) TETRAHYDRO-ISOQUINOLINES AND RELATED COMPOUNDS AS MODULATORS OF GPR65 | Pathios Therapeutics Limited (GB) | 2023-06-08 | — | — | US | disclosed |
| US-20230174530-A1 | N-(PHENYLAMINOCARBONYL) TETRAHYDRO-ISOQUINOLINES AND RELATED COMPOUNDS AS MODULATORS OF GPR65 | Pathios Therapeutics Limited (GB) | 2023-06-08 | — | — | US | disclosed |
| US-20230174530-A1 | N-(PHENYLAMINOCARBONYL) TETRAHYDRO-ISOQUINOLINES AND RELATED COMPOUNDS AS MODULATORS OF GPR65 | Pathios Therapeutics Limited (GB) | 2023-06-08 | — | — | US | disclosed |
| EP-4161643-A1 | N-(PHENYLAMINOCARBONYL) TETRAHYDRO-ISOQUINOLINES AND RELATED COMPOUNDS AS MODULATORS OF GPR65 | Pathios Therapeutics Limited (GB) | 2023-04-12 | — | — | EP | disclosed |
| WO-2021245426-A1 | N-(PHENYLAMINOCARBONYL) TETRAHYDRO-ISOQUINOLINES AND RELATED COMPOUNDS AS MODULATORS OF GPR65 | Pathios Therapeutics Limited (GB) | 2021-12-09 | — | — | WO | disclosed |
| EP-1637521-B1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-7872133-B2 | Tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20060154944-A1 | Novel tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-13 | — | — | US | disclosed |
| EP-1637521-A1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154944-A1 | Novel tricyclic heterocycle compound | CYP11B1, CYP11B2, HCCS | KMT2A 2539/4885MEN1 1017/4885GAA 1007/4885 |
| US-20230174530-A1 | N-(PHENYLAMINOCARBONYL) TETRAHYDRO-ISOQUINOLINES AND RELATED COMPOUNDS AS MODULATORS OF GPR65 | GPR3, GPR65, GPR52 | KMT2A 2819/4885MEN1 4615/4885GAA 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.